Get the Stockscreener App
1.60
4.76%
-0.08
Okyo Pharma Limited stock is traded at $1.60, with a volume of 33,134.
It is down -4.76% in the last 24 hours and down -4.76% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.68
Open:
$1.62
24h Volume:
33,134
Relative Volume:
0.19
Market Cap:
$83.97M
Revenue:
-
Net Income/Loss:
$-4.61M
P/E Ratio:
-12.76
EPS:
-0.1254
Net Cash Flow:
$-3.10M
1W Performance:
+1.27%
1M Performance:
-4.76%
6M Performance:
-41.18%
1Y Performance:
+8.47%
1-Day Range:
$1.59
$1.65
1-Week Range:
$1.52
$1.72
52-Week Range:
$1.32
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.60 | 83.97M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Piper Sandler | Overweight |
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April - MarketBeat
OKYO Pharma to present at Eyecelerator, share urcosimod data at ARVO annual meeting - Proactive financial news
OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver - TipRanks
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May - The Manila Times
OKYO Pharma (NASDAQ: OKYO) showcases urcosimod NCP data at Eyecelerator and ARVO - Stock Titan
Denver eye meetings put OKYO’s CEO and eye-pain drug study on stage - Stock Titan
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March - MarketBeat
Aug Action: How does OKYO Pharma Limited compare to its peers - baoquankhu1.vn
Piper Sandler Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Sentiment: Is OKYO Pharma Limited a turnaround storyMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Gap Down: Can OKYO Pharma Limited beat the S P 5002026 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
OKYO Pharma to hold advisory board meeting at ASCRS conference By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting - Sahm
Small cap wrap: Replenish Nutrients, OKYO Pharma, Bit Digital, Record Resources… - Proactive financial news
OKYO Pharma to hold advisory board meeting at ASCRS annual event - Investing.com India
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026 - Yahoo Finance
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting - TipRanks
OKYO Pharma to hold advisory board meeting at ASCRS annual event By Investing.com - Investing.com South Africa
OKYO Pharma to hold advisory board meeting at ASCRS conference - Investing.com
OKYO Pharma (OKYO) showcases urcosimod Phase 2 data and plans 150-patient trial - Stock Titan
OKYO Pharma Announces Scientific Advisory Board Meeting and - GlobeNewswire
OKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentation - Proactive financial news
OKYO Pharma LTD - Via Ritzau
Income Plays: Is OKYO Pharma Limited stock trending bullishPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
OKYO SEC FilingsOKYO PHARMA LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-03-31 02:21:38 - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - The Globe and Mail
OKYO Pharma director acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
OKYO Pharma director acquires additional shares on NASDAQ - Investing.com UK
OKYO Pharma executive chairman increases stake with share purchase - Proactive Investors
OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks
OKYO Pharma Announces Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan
OKYO Pharma director acquires 30,980 shares, increases total holding By Investing.com - in.investing.com
OKYO Pharma announces director stock purchase - proactiveinvestors.com
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks
OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com
OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) CDO buys 30,980 shares at $1.59 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India
OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):